P027 | LONG-TERM RESPONSE AND TREATMENT PERSISTENCE IN THE ANTI-CGRP ERA: A REAL-WORLD STUDY
Confinia Cephalalgica · 03.11.2026 · 36 (s1)
DOI: 10.4081/cc.2026.15983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
New therapies targeting the calcitonin gene-related peptide (CGRP) pathway have transformed migraine prophylaxis by addressing the limitations of standard preventives, with efficacy that appears stable across successive treatment cycles. In this registry-based study, we aimed to evaluate the long-term response and treatment persistence of patients receiving anti-CGRP therapies in a real-world setting throughout the extended period following their introduction into routine clinical practice.
Methods
We retrospectively analyzed patients followed at our headache center and treated with anti-CGRP preventive therapies. We assessed reduction in monthly headache days (MHDs) and monthly analgesic medications (MAMs) from baseline, focusing on response stability and treatment persistence. We also evaluated the occurrence of a reduction in treatment efficacy over time based on changes in headache frequency. Reasons for treatment discontinuation were recorded.
Results
132 patients were included: 114 (87%) were women; the mean age was 46±12.7 years. At baseline, 71 (62.3%) patients were affected by chronic migraine, while 62 (60.2%) had medication overuse headache. The mean disease duration was 29.2±13.6 years. The mean treatment duration was 27.5±13.9 months: 64 patients achieved a ≥75% reduction in MHDs, 33 achieved a ≥50% reduction, whereas only 3 achieved a ≥30% reduction from baseline. Only 6 patients experienced no benefit. Notably, 26 patients were lost to follow-up, and 12 of them did not attend the first scheduled 3-month visit after prescription. 10 patients experienced a gradual reduction in efficacy over time. Compared with those with a sustained response, patients with a partial loss of efficacy had higher baseline MHDs (p=0.02), higher baseline MAMs (p=0.01), and a higher prevalence of psychiatric comorbidities and chronic pain syndromes (p
Zitieren
APA
(2026). P027 | LONG-TERM RESPONSE AND TREATMENT PERSISTENCE IN THE ANTI-CGRP ERA: A REAL-WORLD STUDY. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.15983
Vancouver
P027 | LONG-TERM RESPONSE AND TREATMENT PERSISTENCE IN THE ANTI-CGRP ERA: A REAL-WORLD STUDY. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.15983
BibTeX
@article{euvimed2026,
title = {P027 | LONG-TERM RESPONSE AND TREATMENT PERSISTENCE IN THE ANTI-CGRP ERA: A REAL-WORLD STUDY},
journal = {Confinia Cephalalgica},
year = {2026},
volume = {36},
number = {s1},
doi = {10.4081/cc.2026.15983}
}
EUVIMED